Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma

Objective. To compare the clinical efficacy and long-term survival between anlotinib monotherapy and anlotinib plus docetaxel in patients with lung carcinoma. Methods. Between October 2019 and December 2021, 84 patients with lung cancer diagnosed and treated at our hospital were enrolled and randoml...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers 2022, Vol.2022, p.2483816-6
Main Authors: Ji, Xiang, Jing, Xin, Liu, Yongshi, Huang, Jiangbo, Yang, Sanhu, Yun, Yuhui
Format: Article
Language:English
Subjects:
Anemia
Angiogenesis
Cancer therapies
Carcinoma
Chemotherapy
Clinical medicine
Data analysis
Docetaxel - therapeutic use
Drug therapy
Effectiveness
Fever
Humans
Liver
Lung - pathology
Lung cancer
Lung carcinoma
Lung Neoplasms - pathology
Medical prognosis
Metastasis
Mortality
Nausea
Patients
Pharmaceuticals
Proteinuria
Renal function
Sample size
Side effects
Survival
Treatment Outcome
Tumors
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To compare the clinical efficacy and long-term survival between anlotinib monotherapy and anlotinib plus docetaxel in patients with lung carcinoma. Methods. Between October 2019 and December 2021, 84 patients with lung cancer diagnosed and treated at our hospital were enrolled and randomly allocated to the control (n=42) and experimental (n=42) groups. Patients in the control group only received anlotinib, whereas those in the experimental group were administered both anlotinib and docetaxel. The clinical effectiveness, long-term survival, and other associated variables of the two groups were compared. Results. There were no CR cases, 7 PR cases, 22 SD cases, and 13 PD cases in the control group. In the experimental group, there were 4 cases of CR, 20 cases of CR, 11 cases of SD, and 7 cases of PD. The overall clinical effectiveness of the experimental group was much higher than that of the control group. There were 3 cases of anemia, 5 cases of pyrexia, 6 cases of proteinuria, 9 cases of nausea and vomiting, and 4 cases of abnormal liver and renal function in the control group. (P
ISSN:0278-0240
1875-8630
DOI:10.1155/2022/2483816